Canada approves GSK’s Arexvy vaccine for RSV protection in adults 50-59 at elevated risk

Pallavi Madhiraju- November 7, 2024 0

In a crucial development for public health, Health Canada has extended its approval for GlaxoSmithKline's Arexvy vaccine to include adults aged 50 to 59 who ... Read More

EC approves Pfizer’s ABRYSVO RSV vaccine for infants and older adults

Pallavi Madhiraju- August 28, 2023 0

Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for ABRYSVO, its bivalent respiratory syncytial virus (RSV) prefusion F vaccine. This groundbreaking ... Read More

FDA greenlights Pfizer’s ABRYSVO vaccine for shielding infants from RSV

Pallavi Madhiraju- August 23, 2023 0

The US Food and Drug Administration (FDA) has granted approval to Pfizer Inc.'s ABRYSVO, a bivalent Respiratory Syncytial Virus prefusion F (RSVpreF) vaccine. This cutting-edge ... Read More